Abstract 314P
Background
There is insufficient evidence on the neoadjuvant use of bevacizumab before interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the perioperative outcomes in a cohort of women who underwent IDS after receiving bevacizumab added to neoadjuvant chemotherapy (Bev-NACT).
Methods
We retrospectively reviewed the medical records of all women with advanced EOC who underwent IDS between March 2021 and June 2022 after receiving Bev-NACT at Tata Medical Center. Relevant information was extracted from electronic medical records. Appropriate descriptive and survival statistics were used in the analysis.
Results
A total of 33 women underwent IDS after Bev-NACT. Stage IIIC, stage IVA, and stage IVB disease were present in 51.5%, 12.1%, and 36.4% of cases. The most common histology was high-grade serous carcinoma (95%). The median number of bevacizumab cycles received was 3 (2-5). The objective response rate with Bev-NACT was 90.9%. Complete cytoreduction at IDS was achieved in 75.8%. Chemotherapy response score was 1 in 6.1%, 2 in 72.7%, and 3 in 21.2%. Surgical complications of Clavien-Dindo grade 3 or higher occurred in 24.2% of patients. Serious adverse events attributable to bevacizumab occurred in 12.1% (fistula 3%, wound complications 3%, venous thromboembolism 3%, haemorrhage 3%), and the 30-day postoperative death rate was 3%. Median progression-free survival (PFS) was 23 months (95% CI 18-34), and the estimated 3-year PFS rate was 32%.
Conclusions
Bevacizumab added to neoadjuvant chemotherapy before IDS for advanced EOC had an acceptable safety and promising efficacy. Neoadjuvant bevacizumab in advanced EOC needs to be further evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract